The FDA announced the approval of Beleodaq (belinostat; Spectrum Pharmaceuticals) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). Beleodaq is a pan HDAC inhibitor that works by stopping enzymes that contribute to T-cells becoming cancerous.
The safety and effectiveness of Beleodaq was evaluated in a clinical study involving 129 participants with relapsed or refractory PTCL. All participants were treated with Beleodaq until their disease progressed or side effects became unacceptable. Results demonstrated that 25.8% of participants had a complete response or partial response after treatment.
For more information call (877) 387-4538 or visit Sppirx.com.
This article originally appeared on MPR